84 related articles for article (PubMed ID: 19910218)
1. Dynamic contrast enhancement of experimental glioma an intra-individual comparative study to assess the optimal time delay.
Engelhorn T; Schwarz MA; Eyupoglu IY; Kloska SP; Struffert T; Doerfler A
Acad Radiol; 2010 Feb; 17(2):188-93. PubMed ID: 19910218
[TBL] [Abstract][Full Text] [Related]
2. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques.
Wintersperger BJ; Runge VM; Biswas J; Reiser MF; Schoenberg SO
Invest Radiol; 2007 Aug; 42(8):558-63. PubMed ID: 17620938
[TBL] [Abstract][Full Text] [Related]
3. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.
Morelli JN; Runge VM; Vu L; Loynachan AT; Attenberger UI
Invest Radiol; 2010 Dec; 45(12):810-8. PubMed ID: 20856127
[TBL] [Abstract][Full Text] [Related]
5. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents.
Wintersperger BJ; Runge VM; Tweedle MF; Jackson CB; Reiser MF
Invest Radiol; 2009 Feb; 44(2):89-94. PubMed ID: 19077910
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI.
Hirschberg H; Wu GN; Madsen SJ
Minim Invasive Neurosurg; 2007 Dec; 50(6):318-23. PubMed ID: 18210352
[TBL] [Abstract][Full Text] [Related]
8. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.
Essig M; Tartaro A; Tartaglione T; Pirovano G; Kirchin MA; Spinazzi A
Acad Radiol; 2006 Jun; 13(6):744-51. PubMed ID: 16679277
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model.
Runge VM; Biswas J; Wintersperger BJ; Baumann SS; Jackson CB; Herborn CU; Patel T
Invest Radiol; 2006 Mar; 41(3):244-8. PubMed ID: 16481906
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Gd-DTPA-induced signal enhancements in rat brain C6 glioma among different pulse sequences in 3-Tesla magnetic resonance imaging.
Sato H; Enmi J; Teramoto N; Hayashi T; Yamamoto A; Tsuji T; Naito H; Iida H
Acta Radiol; 2008 Mar; 49(2):172-9. PubMed ID: 18300142
[TBL] [Abstract][Full Text] [Related]
11. Quantitative estimation of dynamic contrast enhanced MRI parameters in rat brain gliomas using a dual surface coil system.
Pickup S; Chawla S; Poptani H
Acad Radiol; 2009 Mar; 16(3):341-50. PubMed ID: 19201363
[TBL] [Abstract][Full Text] [Related]
12. Contrast/Noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate low-grade from high-grade cerebral gliomas.
Fayed N; Morales H; Modrego PJ; Pina MA
Acad Radiol; 2006 Jun; 13(6):728-37. PubMed ID: 16679275
[TBL] [Abstract][Full Text] [Related]
13. Enhancement in a brain glioma model: a comparison of half-dose gadobenate dimeglumine versus full-dose gadopentetate dimeglumine at 1.5 and 3 T.
Morelli JN; Gerdes CM; Zhang W; Williams JM; Saettele MR; Ai F
J Magn Reson Imaging; 2013 Aug; 38(2):306-11. PubMed ID: 23737259
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T.
Attenberger UI; Runge VM; Morelli JN; Williams J; Jackson CB; Michaely HJ
J Magn Reson Imaging; 2010 Mar; 31(3):549-55. PubMed ID: 20187196
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions.
Uysal E; Erturk SM; Yildirim H; Seleker F; Basak M
AJR Am J Roentgenol; 2007 Mar; 188(3):697-702. PubMed ID: 17312056
[TBL] [Abstract][Full Text] [Related]
16. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced susceptibility-weighted perfusion MRI (DSC-MRI) in a glioma model of the rat brain using a conventional receive-only surface coil with a inner diameter of 47 mm at a clinical 1.5 T scanner.
Ulmer S; Reeh M; Krause J; Herdegen T; Heldt-Feindt J; Jansen O; Rohr A
J Neurosci Methods; 2008 Jul; 172(2):168-72. PubMed ID: 18538856
[TBL] [Abstract][Full Text] [Related]
18. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors.
Kubota T; Yamada K; Kizu O; Hirota T; Ito H; Ishihara K; Nishimura T
J Magn Reson Imaging; 2005 Jun; 21(6):694-700. PubMed ID: 15906343
[TBL] [Abstract][Full Text] [Related]
19. Fat-suppressed dynamic and delayed gadolinium-enhanced volumetric interpolated breath-hold magnetic resonance imaging of cholangiocarcinoma.
Leyendecker JR; Gakhal M; Elsayes KM; McDermott R; Narra VR; Brown JJ
J Comput Assist Tomogr; 2008; 32(2):178-84. PubMed ID: 18379298
[TBL] [Abstract][Full Text] [Related]
20. Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla.
Klumpp B; Fenchel M; Hoevelborn T; Helber U; Scheule A; Claussen C; Miller S
Invest Radiol; 2006 Sep; 41(9):661-7. PubMed ID: 16896300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
